P102 Dissecting the metabolic impact of faecal microbiota transplantation (FMT) in C. difficile and E. coli infections using 3D OrbiSIMS
(2024)
Presentation / Conference Contribution
Qassadi, F., Kim, D.-H., Griffiths, R., Kao, D., Zhu, Z., & Monaghan, T. (2024, June). P102 Dissecting the metabolic impact of faecal microbiota transplantation (FMT) in C. difficile and E. coli infections using 3D OrbiSIMS. Presented at BSG LIVE’24, Birmingham, UK
Outputs (7)
Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention (2023)
Journal Article
Monaghan, T. M., Ugun-Klusek, A., Finelli, M., Gurnani, P., Chakrabarti, L., Kao, D., Alexander, C., & Polytarchou, C. (2024). Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention. Gut, 73(6), 1034-1036. https://doi.org/10.1136/gutjnl-2022-327301
Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria (2023)
Journal Article
Qassadi, F. I., Zhu, Z., & Monaghan, T. M. (2023). Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria. Pathogens, 12(2), Article 333. https://doi.org/10.3390/pathogens12020333The rising burden of antimicrobial resistance and increasing infectious disease outbreaks, including the recent COVID-19 pandemic, has led to a growing demand for the development of natural products as a valuable source of leading medicinal compounds... Read More about Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria.
Therapeutic potential of miRNAs in Clostridioides difficile infection (2022)
Journal Article
Monaghan, T. M., Polytarchou, C., Kao, D., Alexander, C., & Gurnani, P. (2022). Therapeutic potential of miRNAs in Clostridioides difficile infection. Future Microbiology, 17(5), 315-318. https://doi.org/10.2217/fmb-2021-0311Treating Clostridioides difficile infection with miRNAs alone or combined with live biotherapeutic products may augment therapeutic efficacy and help counteract drug resistance in the future.
Therapeutic potential of miRNAs in Clostridioides difficile infection (2022)
Journal Article
Monaghan, T. M., Polytarchou, C., Kao, D., Alexander, C., & Gurnani, P. (2022). Therapeutic potential of miRNAs in Clostridioides difficile infection. Future Microbiology, 17(5), https://doi.org/10.2217/fmb-2021-0311Treating C. difficile infection with miRNAs alone or combined with live biotherapeutic products may augment therapeutic efficacy and help counteract drug resistance in the future.
Clostridioides difficile: innovations in target discovery and potential for therapeutic success (2021)
Journal Article
Monaghan, T. M., Seekatz, A. M., Mullish, B. H., Moore-Gillon, C. E., Dawson, L., Ahmed, A., Kao, D., & Chan, W. C. (2021). Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opinion on Therapeutic Targets, 25(11), 949-963. https://doi.org/10.1080/14728222.2021.2008907Introduction: Clostridioides difficile infection (CDI) remains a worldwide clinical problem. Increased incidence of primary infection, occurrence of hypertoxigenic ribotypes, and more frequent occurrence of drug resistant, recurrent, and non-hospital... Read More about Clostridioides difficile: innovations in target discovery and potential for therapeutic success.
Novel lactoferrin-loaded alginate microbeads display anti-Clostridium difficile defence properties (2018)
Journal Article
Monaghan, T. M., Braim, S., Spiewak, K., Brindell, M., & Alexander, C. (2018). Novel lactoferrin-loaded alginate microbeads display anti-Clostridium difficile defence properties. Gut, 67(Supp 1), Article A194-A195. https://doi.org/10.1136/gutjnl-2018-BSGAbstracts.387